Precision Oncology News: Sutter Health Exploring In-House ctDNA Testing in Effort to Expand Precision Oncology Access
An in-depth article in GenomeWeb's Precision Oncology News highlights Sutter Health’s work with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
"While most organizations are still outsourcing NGS testing, health institutions are increasingly implementing local testing strategies. In a 2019 precision oncology survey of oncologists and pathologists conducted by Novartis, 83 percent said their organizations send out NGS testing to third-party labs. However, there was a 58 percent increase from 2018 to 2019 in respondents reporting they had in-house NGS testing. Faster turnaround time and better management of patients' data were among the top advantages cited for in-house NGS testing."